Observations from ID and Beyond: Should We Prescribe Nirmatrelvir/r (Paxlovid) to Low-Risk COVID-19 Patients?

In HIV and ID Observations, Dr. Paul Sax explains the views for and against prescribing Paxlovid for COVID-19 patients at low-risk for severe outcomes.

The top recommended treatment for high-risk outpatients with COVID-19 in the NIH guidelines is nirmatrelvir/r (Paxlovid). In the latest HIV and ID Observations, Dr. Paul Sax examines whether it should be prescribed to low-risk patients too.

Do you want to be notified whenever Dr. Sax posts? Sign up to receive notifications by email by using the Subscribe box.

Want to see more from NEJM Journal Watch? Register here.

Observations from ID and Beyond: Should We Prescribe Nirmatrelvir/r (Paxlovid) to Low-Risk COVID-19 Patients?

Topics